Robert S. Rosenson

27.0k citations

386 papers · 16.6k indexed · 14 hit papers · h-index 61

Impact in

Endocrinology, Diabetes and Metabolism top 0.1%
- Diabetes, Cardiovascular Risks, and Lipoproteins
Cardiology and Cardiovascular Medicine top 0.2%
- Lipid metabolism and disorders

Papers in

Endocrinology, Diabetes and Metabolism 126
- Diabetes, Cardiovascular Risks, and Lipoproteins 108
Surgery 261
- Lipoproteins and Cardiovascular Health 244

Co-authors: Christy Tangney James D. Otvos H. Bryan Brewer Anatol Kontush Paul Muntner Alan R. Tall Wolfgang Köenig M. John Chapman
Journals: Journal of the American College of Cardiology (44 papers)Cardiovascular Drugs and Therapy (40 papers)Atherosclerosis (28 papers)Circulation (26 papers)Journal of clinical lipidology (23 papers)
Partner nations: United States Canada Australia

In The Last Decade

Robert S. Rosenson

375 papers receiving 16.1k citations

Hit Papers

14 papers align trajectories log scale

Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia 2024 · 103 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2024 New England Journal of Medicine
2024 JAMA Cardiology
2024 New England Journal of Medicine
2022 New England Journal of Medicine
2020 New England Journal of Medicine
2020 New England Journal of Medicine
2019 European Heart Journal
2016 JAMA
2015 Nature Reviews Cardiology
2014 Journal of the American College of Cardiology
2012 Circulation
2011 Clinical Chemistry
2009 Circulation
1998 JAMA

Peers

Countries citing papers authored by Robert S. Rosenson

Since Specialization

Citations

This map shows the geographic impact of Robert S. Rosenson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert S. Rosenson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert S. Rosenson more than expected).

Fields of papers citing papers by Robert S. Rosenson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert S. Rosenson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert S. Rosenson. The network helps show where Robert S. Rosenson may publish in the future.

Co-authors

The 25 scholars most cited alongside Robert S. Rosenson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Robert S. Rosenson Line = papers co-authored together Robert S. Rosenson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Efficacy of evinacumab in patients with severe hypertriglyceridemia and a history of severe hypertriglyceridemia-related acute pancreatitis: A phase 2b trial Journal of clinical lipidology ·Robert S. Rosenson, Richard T. De George, Robert J. Sanchez, Xue-Qiao Zhao, Manish P. Ponda, Freeman Ne, Robert Pordy	2025	1
2	Challenges in achieving LDL cholesterol targets and novel approaches to lipid lowering European Journal of Preventive Cardiology ·Waqas Malick, Daein Choi, Anne Langsted, Vera Bittner, Børge G. Nordestgaard, Erik S.G. Stroes, Robert S. Rosenson	2025	2
3	Intraindividual Variability in Serial Lipoprotein(a) Concentrations Among Placebo-Treated Patients in the OCEAN(a)-DOSE Trial Journal of the American College of Cardiology ·Prakriti Gaba, Robert S. Rosenson, J. Antonio G. López, Gerald F. Watts, Thorsten M. Leucker, Julia Kuder, KyungAh Im, Helina Kassahun, Huei Wang, You Wu, Jingying Wang, E. Magnus Ohman, Marc S. Sabatine, Michelle L. O’Donoghue	2024	10
4	Exome sequence analysis identifies rare coding variants associated with a machine learning-based marker for coronary artery disease Nature Genetics ·Ben Omega Petrazzini, Iain S. Forrest, Ghislain Rocheleau, Ha My T. Vy, Carla Márquez‐Luna, Áine Duffy, Qiming Zhang, Joshua K. Park, 賢太粟津, Sascha N. Goonewardena, Waqas Malick, Robert S. Rosenson, Daniel M. Jordan, Ron Do	2024	9
5	Genetics and Pathophysiological Mechanisms of Lipoprotein(a)‐Associated Cardiovascular Risk Journal of the American Heart Association ·Annabelle Santos Volgman, Marlys L. Koschinsky, Anurag Mehta, Robert S. Rosenson	2024	16
6	Monocyte-Mediated Thrombosis Linked to Circulating Tissue Factor and Immune Paralysis in COVID-19 Arteriosclerosis Thrombosis and Vascular Biology ·Sascha N. Goonewardena, Qinzhong Chen, JEREMY TAYLOR, Leonard Bolgar, Kristaps Felzenbergs, Pennelope Blakely, Salim S. Hayek, David J. Pinsky, Robert S. Rosenson	2024	3
7	Primary Prevention of Subclinical Atherosclerosis in Young Adults Journal of the American College of Cardiology ·Ana Devesa, Borja Ibáñez, Waqas Malick, Nguyen Phuong Ngoc, А А Каленова, 萧高洪, Robert S. Rosenson, Deepak L. Bhatt, Gregg W. Stone, Valentı́n Fuster	2023	39
8	Intensity of Lipid-Lowering Therapy Among Patients With Polyvascular Disease JAMA Network Open ·Benjamin E. Peterson, Deepak L. Bhatt, Christie M. Ballantyne, James A. de Lemos, Robert S. Rosenson, Mikhail Kosiborod, Christopher P. Cannon, (unknown)	2023	4
9	The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis Nature Reviews Cardiology ·Karan Sud, Navneet Narula, Elena Aïkawa, Eloisa Arbustini, Philippe Pîbarot, Giampaolo Merlini, Robert S. Rosenson, Surya V. Seshan, Edgar Argulian, Amir Ahmadi, Fang Zhou, Van Vo Kim Hieu, Nancy Côté, Sotirios Tsimikas, Valentı́n Fuster, Sam Gandy, Robert O. Bonow, Olga Gursky, Jagat Narula	2023	18
10	Incident CHD and ischemic stroke associated with lipoprotein(a) by levels of Factor VIII and inflammation Journal of clinical lipidology ·Lisandro D. Colantonio, Sascha N. Goonewardena, Zhixin Wang, Elizabeth A. Jackson, Michael E. Farkouh, 信男徳松, Waqas Malick, Shia T. Kent, J. Antonio G. López, Paul Muntner, Vera Bittner, Robert S. Rosenson	2023	5
11	Repurposing low-dose naltrexone for the prevention and treatment of immunothrombosis in COVID-19 European Heart Journal - Cardiovascular Pharmacotherapy ·Bertram Pitt, JEREMY TAYLOR, David Gluck, Robert S. Rosenson, Sascha N. Goonewardena	2022	13
12	Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization Between 2015 and 2019 Circulation Cardiovascular Quality and Outcomes ·Alexander R. Zheutlin, Catherine G. Derington, Jennifer S. Herrick, Robert S. Rosenson, 康一吉井, Monika M. Safford, Todd M. Brown, Elizabeth A. Jackson, Mark Woodward, Stephanie Reading, Kate K. Orroth, Rаkhimоv Mukhаmmаdjоn Rо’ ziyеviсh, Salim S. Virani, Paul Muntner, Adam P. Bress	2022	12
13	Lipoprotein(a) and the Risk for Coronary Heart Disease and Ischemic Stroke Events Among Black and White Adults With Cardiovascular Disease Journal of the American Heart Association ·Lisandro D. Colantonio, Vera Bittner, Monika M. Safford, Santica M. Marcovina, Todd M. Brown, Elizabeth A. Jackson, 信男徳松, J. Antonio G. López, Keri L. Monda, Timothy B. Plante, Shia T. Kent, Paul Muntner, Robert S. Rosenson	2022	19
14	Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction Journal of clinical lipidology ·A`bd Ol-Hamid Mahiyaneh, Vera Bittner, Shahzad, 李剑光, Lisandro D. Colantonio, Rаkhimоv Mukhаmmаdjоn Rо’ ziyеviсh, 均高瀬, Stephanie Reading, Robert S. Rosenson, Paul Muntner	2021	5
15	A new phenotypic classification system for dyslipidemias based on the standard lipid panel Lipids in Health and Disease ·Maureen Sampson, Rami A. Ballout, Daniel Soffer, Anna Wolska, Philip Chair, Jeff W. Meeusen, Leslie J. Donato, Adham Sherif, James D. Otvos, Eliot A. Brinton, Robert S. Rosenson, Peter W.F. Wilson, Marcelo Amar, Robert D. Shamburek, Sotirios K. Karathanasis, Alan T. Remaley	2021	11
16	What Do US Physicians and Patients Think About Lipid‐Lowering Therapy and Goals of Treatment? Results From the GOULD Registry Journal of the American Heart Association ·Suzanne V. Arnold, Christopher P. Cannon, James A. de Lemos, Robert S. Rosenson, Christie M. Ballantyne, Yuyin Liu, Zhao Xua, Katherine E. Mues, Deepak L. Bhatt, Mikhail Kosiborod, (unknown)	2021	14
17	Race/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction Journal of clinical lipidology ·エリックザスマン, 康一吉井, Adam P. Bress, Catherine G. Derington, Jordan B. King, Ying Wen, Ligong Chen, Vera Bittner, Todd M. Brown, Keri L. Monda, Katherine E. Mues, Robert S. Rosenson, Elizabeth A. Jackson, Paul Muntner, Lisandro D. Colantonio	2021	18
18	PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults Journal of Lipid Research ·Matthew T. Mefford, Santica M. Marcovina, Vera Bittner, Mary Cushman, Todd M. Brown, Michael E. Farkouh, Sotirios Tsimikas, Keri L. Monda, J. Antonio G. López, Paul Muntner, Robert S. Rosenson	2019	8
19	Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials European Heart Journal ·Paul Guedeney, Gennaro Giustino, Sabato Sorrentino, Bimmer E. Claessen, Anton Camaj, Deborah N. Kalkman, Birgit Vogel, Samantha Sartori, Salvatore De Rosa, Usman Baber, Ciro Indolfi, Gilles Montalescot, George Dangas, Robert S. Rosenson, Stuart Pocock, Roxana Mehran	2019	147
20	Functional Assessment of HDL: Moving Beyond Static Measures for Risk Assessment Cardiovascular Drugs and Therapy ·Robert S. Rosenson	2010	16

About Robert S. Rosenson

Robert S. Rosenson is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery, Cardiology and Cardiovascular Medicine, Cancer Research and Economics and Econometrics, having authored 386 papers that have together received 16.6k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (244 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (108 papers), Cancer, Lipids, and Metabolism (61 papers), Lipid metabolism and disorders (56 papers), Health Systems, Economic Evaluations, Quality of Life (47 papers), Pharmaceutical Economics and Policy (43 papers), Blood properties and coagulation (32 papers) and Adipokines, Inflammation, and Metabolic Diseases (22 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (4.8k citations), Cardiology and Cardiovascular Medicine (5.1k citations), Surgery (8.7k citations), Cancer Research (2.2k citations) and Immunology (1.5k citations). Robert S. Rosenson has collaborated with scholars based in United States, Canada and Australia. Frequent co-authors include Christy Tangney, James D. Otvos, H. Bryan Brewer, Anatol Kontush, Paul Muntner, Alan R. Tall, Wolfgang Köenig, M. John Chapman, Daniel Gaudet and Philip J. Barter. Their work appears in journals such as Journal of the American College of Cardiology, Cardiovascular Drugs and Therapy, Atherosclerosis, Circulation and Journal of clinical lipidology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact